MAPT and synucleinopathy: However, subjects with AD had higher pancreatic tau immunoreactivity than controls (p < 0.0001), subjects with a normal neuropathological examination and a history of T2DM (p < 0.0001) or subjects with synucleinopathy (p < 0.0001).